Ivosidenib

Ivosidenib 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Acute Myeloid Leukemia With Gene Mutations、Acute Myeloid Leukemia。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

24 项

全球在招研究

7 项

已进入 III/IV 期

25 个

开展国家和地区

有

中国境内设点

药品与企业信息

研发企业

PETHEMA Foundation
Memorial Sloan Kettering Cancer Center
UNICANCER
M.D. Anderson Cancer Center
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Beat AML, LLC
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Acute Leukemia French Association

汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。

生产企业

公开药品批准资料或正式说明书暂未提供明确的生产企业信息。

研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。

主要开展国家和地区

比利时、法国、英国、美国、德国、Czechia、意大利、Jordan、Lithuania、Portugal、Romania、西班牙

正在招募患者的 Ivosidenib 研究

中国患者怎么争取用上这款药

这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。

同类方向的其他在研新药

Carboplatin Pembrolizumab Cyclophosphamide Rituximab Venetoclax Azacitidine Dexamethasone Doxorubicin

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。

Ivosidenib

药品与企业信息

研发企业

生产企业

主要开展国家和地区

正在招募患者的 Ivosidenib 研究

Personalized Medicine for Advanced Biliary Cancer Patients

CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.

A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia

Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)

Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML

Ivosidenib Plus mFOLFOXIRI and Celecoxib for BRAF-targeted Therapy-refractory BRAF V600E-mutant Colorectal Cancer Patients

Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 or 2 Systemic Treatment Regimens

Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation

Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients

OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia

Ivosidenib as Post-HSCT Maintenance for AML

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

Study of SA+X in the Treatment of Newly Diagnosed AML

Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation

Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy

A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment

Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS

Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.

中国患者怎么争取用上这款药

同类方向的其他在研新药